SCHEMBL6530658

SCHEMBL6530658

O=C(Nc1ccc(Oc2ccnc3[nH]c(=O)c4ccccc4c23)cc1)c1cc(Cl)cnc1Cl

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AURKA O14965 17/20 0.52
AURKB Q96GD4 16/20 0.52
CHEK2 O96017 2/20 0.48
RET P07949 2/20 0.48
FLT4 P35916 2/20 0.48
LIMK1 P53667 2/20 0.48
MAPK13 O15264 1/20 0.48
NTRK1 P04629 1/20 0.48
HCK P08631 1/20 0.48
FGFR1 P11362 1/20 0.48
SIK1 P57059 1/20 0.48
TNK2 Q07912 1/20 0.48
WNK3 Q9BYP7 1/20 0.48
KDR P35968 1/20 0.47
CSF1R P07333 1/20 0.46
ABL2 P42684 1/20 0.46
BLK P51451 1/20 0.46
MET P08581 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6525300 0.88 BRAF (0.47) AURKAAURKBCHEK2RETFLT4
SCHEMBL6522704 0.88 AURKA (0.51) AURKAAURKBKDRMET
SCHEMBL6523535 0.82 AURKA (0.69) AURKAAURKBCHEK2RETFLT4
SCHEMBL6523569 0.80 AURKA (0.53) AURKAAURKBCHEK2RETFLT4
SCHEMBL3453781 0.76 AURKA (0.58) AURKAAURKBCHEK2RETFLT4
SCHEMBL6519343 0.76 AURKA (0.56) AURKAAURKB
SCHEMBL12786959 0.75 AURKA (0.76) AURKAAURKBKDRMET
SCHEMBL6524888 0.75 AURKA (0.52) AURKAAURKBCHEK2RETFLT4
SCHEMBL6517366 0.74 AURKA (0.53) AURKAAURKBCHEK2RETFLT4
SCHEMBL6525321 0.74 AURKA (0.53) AURKAAURKBCHEK2RETFLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 AURKA 538/4885AURKB 487/4885CHEK2 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.